研究利妥昔单抗在肌痛脑脊液/慢性疲劳综合征(ME/CFS)中的功效和安全性研究
探索性的,安慰剂对照的双盲,II期研究,对利妥昔单抗(基因重组)在肌痛脑脊液/慢性疲劳综合征(ME/CFS)中的功效和安全性研究(遗传重组)
The efficacy and safety of rituximab on ME/CFS symptoms after administration to patients with myalgic encephalomyelitis/chronic fatigue syndrome will be compared in an exploratory, placebo-controlled, double-blind fashion. In the subsequent secondary evaluation period, subjects who received rituximab in the primary evaluation period will receive placebo, and the timing and duration of rituximab's effect will be explored throughout the entire evaluation period. Subjects who received placebo during the primary evaluation period will receive rituximab during the secondary evaluation period to explore changes in endpoints before and after switching from placebo to rituximab in the same subjects.
研究概览
详细说明
The efficacy and safety of rituximab (genetical recombination), a CD20 antibody, on ME/CFS symptoms after administration to patients with myalgic encephalomyelitis/chronic fatigue syndrome will be compared in an exploratory, placebo-controlled, double-blind fashion. In the subsequent secondary evaluation period, subjects who received rituximab in the primary evaluation period will receive placebo, and the timing and duration of rituximab's effect will be explored throughout the entire evaluation period. Subjects who received placebo during the primary evaluation period will receive rituximab during the secondary evaluation period to explore changes in endpoints before and after switching from placebo to rituximab in the same subjects.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Takami Ishizuka, PhD
- 电话号码:+081-42-341-2711
- 邮箱:tmc-crso@ncnp.go.jp
学习地点
-
-
Tokyo
-
Kodaira、Tokyo、日本、187-8551
- 招聘中
- National Center of Neurology and Psychiatry
-
接触:
- Takami Ishizuka, PhD
- 电话号码:+81-42-341-2711
- 邮箱:tmc-crso@ncnp.go.jp
-
首席研究员:
- Tomoko Okamoto, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Patients diagnosed with ME/CFS who meet the Canadian criteria by a physician.
- Patients with a severity score of 4 or higher on the Performance Status (PS) based ME/CFS severity classification by the Ministry of Health, Labour and Welfare Research Group
- Patients who are between 18 and 65 years of age at the time of obtaining written consent
- Patients who can be hospitalized (hospitalized from the day before administration and discharged the day after administration) at the time of the first dose of each of the primary and secondary evaluation periods
- Patients whose written consent has been obtained
Exclusion Criteria:
-
Patients with a history of severe hypersensitivity or anaphylactic reactions to components of rituximab or products derived from mouse protein
-
Patients whose cardiopulmonary function is judged by the treating physician to be not maintained
-
Patients complaining of fatigue that does not meet the diagnostic criteria for ME/CFS
-
Patients found to have other medical conditions that may cause symptoms
-
Patients who are pregnant, lactating, or have a positive pregnancy test (serum human chorionic gonadotropin test) at the time of enrollment
-
Patients with coexisting or pre-existing malignant tumors (excluding basal cell carcinoma of the skin and cervical dysplasia)
-
Patients with coexisting or pre-existing severe immune system diseases (excluding autoimmune diseases such as thyroiditis and type 1 diabetes)
-
Patients with a history of systemic immunosuppressive therapy (e.g., immunoglobulin therapy, azathioprine, cyclosporine, mycophenolate mofetil, etc.) within 1 year, a history of receiving drugs such as monoclonal antibodies acting on the immune system (e.g., anti-CD20 antibody products including rituximab), or a history of comorbidities requiring treatment with immunosuppressive drugs Patients with comorbidities requiring treatment with immunosuppressive agents (excluding treatment with low-dose steroids of 5 mg /day or less)
-
Patients who have started alternative medicine (reference: acupuncture, moxibustion, and Japanese warm therapy) within 12 weeks prior to the start of treatment with the investigational drug.
-
Patients with severe endogenous (primary) depression
-
Patients with a neutrophil count <1.5*103/microliter and platelet count <10.0*104/microliter on blood test
-
Patients with impaired renal function (serum creatinine level > 1.5 times the upper limit of the reference value at the institution)
-
Patients with impaired hepatic function (serum bilirubin, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) levels exceeding 1.5 times the upper limit of the reference value of the institution)
-
Patients infected with Human Immunodeficiency Virus (HIV)
-
Patients who test positive for at least one of Hepatitis B surface (HBs) antigen, HBs antibody, Hepatitis B core (HBc) antibody, or Hepatitis C virus (HCV) antibody.
However, patients who meet the following conditions (1) and (2) may be registered.
(i) Patients who are positive for HBs or HBc antibodies and whose HBV-DNA quantification is confirmed to be negative (less than detection sensitivity) and for whom appropriate monitoring, etc. can be conducted in accordance with the Guidelines for Hepatitis B Treatment edited by the Japan Society of Hepatology.
(ii) For patients with positive HCV antibody, when HCV-RNA quantification is negative (less than detection sensitivity)
-
Patients who do not have the ability to comply with the study protocol
-
Patients who have participated in other clinical trials or clinical studies (except for observational studies without intervention) within 16 weeks prior to obtaining consent
-
Other patients who are judged by the investigator or subinvestigator (hereinafter referred to as investigator) to be inappropriate to participate in this clinical trial.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:安慰剂
|
Subjects will be assigned to the rituximab pre-treatment group or placebo pre-treatment group and will receive the study drug (rituximab actual or rituximab placebo) intravenously four times at weekly intervals during the first three weeks of the primary and secondary evaluation periods. |
|
有源比较器:利妥昔单抗(基因重组)
|
Subjects will be assigned to the rituximab pre-treatment group or placebo pre-treatment group and will receive the study drug (rituximab actual or rituximab placebo) intravenously four times at weekly intervals during the first three weeks of the primary and secondary evaluation periods. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Improvement rate
大体时间:From Baseline to the end of treatment at 24 weeks
|
Percentage of cases in which the severity score of ME/CFS based on PS by the MHLW research group improved by 1 or more compared to that before the start of study drug administration (week 0) |
From Baseline to the end of treatment at 24 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
与研究药物开始治疗之前,基于MHLW-PS的ME/CFS严重程度评分在每个评估点(改进率)的患者比例提高了1或更多(第0周)。
大体时间:从基线到第48周的4周间隔
|
从基线到第48周的4周间隔
|
|
|
MHLW研究小组在每个评估点开始使用研究药物开始治疗之前,MHLW研究小组根据PS的严重程度评分的变化量(第0周)
大体时间:从基线到第48周的4周间隔
|
从基线到第48周的4周间隔
|
|
|
Proportion of awake time spent in supine position (%),Proportion of awake time spent in sitting position (%)
大体时间:At 4-week intervals from Baseline up to Week 48
|
Changes in proportions will be aggregated. |
At 4-week intervals from Baseline up to Week 48
|
|
Duration of standing and activity (hours)
大体时间:At 4-week intervals from Baseline up to Week 48
|
Changes in time will be aggregated. |
At 4-week intervals from Baseline up to Week 48
|
|
Fatigue during rest and lying position
大体时间:At 4-week intervals from Baseline up to Week 48
|
Patients will be asked to report the level of fatigue they feel even while lying down, and changes in their fatigue levels will be aggregated. |
At 4-week intervals from Baseline up to Week 48
|
|
Records on exertion and Post-Exertional Malaise (PEM)
大体时间:At 4-week intervals from Baseline up to Week 48
|
Patients will be asked to describe the specific activities they perform and the exhaustion they experience afterward, and a summary table will be created. |
At 4-week intervals from Baseline up to Week 48
|
|
Assessment of fatigue during physical activity
大体时间:At 4-week intervals from Baseline up to Week 48
|
Patients will be asked to report the level of fatigue they experience during physical activity in daily life, and changes in fatigue levels will be aggregated. |
At 4-week intervals from Baseline up to Week 48
|
|
Evaluation based on Fatigue Score
大体时间:At 2-week intervals from Baseline up to Week 48
|
Patients will be asked to complete the Fatigue Score questionnaire, and changes in the score will be aggregated. |
At 2-week intervals from Baseline up to Week 48
|
|
SF-36
大体时间:At 12-week intervals from Baseline up to Week 48
|
Changes in scores obtained from the SF-36 questionnaire will be assessed to evaluate patients' quality of life. |
At 12-week intervals from Baseline up to Week 48
|
|
COMPASS31
大体时间:At 12-week intervals from Baseline up to Week 48
|
Changes in scores obtained from the COMPASS31 questionnaire will be assessed to evaluate patients' autonomic symptoms. |
At 12-week intervals from Baseline up to Week 48
|
|
Pittsburgh Sleep Quality Index (PSQI)
大体时间:At 12-week intervals from Baseline up to Week 48
|
Changes in scores obtained from the PSQI questionnaire will be assessed to evaluate patients' sleep quality. |
At 12-week intervals from Baseline up to Week 48
|
|
Pain intensity
大体时间:At 12-week intervals from Baseline up to Week 48
|
Pain intensity will be assessed using the Visual Analogue Scale (VAS) |
At 12-week intervals from Baseline up to Week 48
|
|
Grip strength
大体时间:At 12-week intervals from Baseline up to Week 48
|
Patients' grip strength will be measured, and changes in the measurements will be aggregated. |
At 12-week intervals from Baseline up to Week 48
|
|
Analysis of the gut microbiota
大体时间:At 24-week intervals from Baseline up to Week 48
|
samples collected from patients will be analyzed, and the composition of the gut microbiota will be aggregated. |
At 24-week intervals from Baseline up to Week 48
|
|
Brain imaging evaluation (Magnetic Resonance Imaging (MRI) of the head, Single Photon Emission Computed Tomography (SPECT) of cerebral blood flow)
大体时间:At 24-week intervals from Baseline up to Week 48
|
Findings from imaging will be aggregated. |
At 24-week intervals from Baseline up to Week 48
|
|
Immune biomarker analysis (qPCR)
大体时间:At 24-week intervals from Baseline up to Week 48
|
qPCR will be measured, and changes in their levels will be aggregated. |
At 24-week intervals from Baseline up to Week 48
|
|
Immune biomarker analysis (anti-autonomic receptor antibody analysis)
大体时间:At 24-week intervals from Baseline up to Week 48
|
Quantify the level of anti-autonomic receptor antibodies will be measured, and changes in their levels will be aggregated. |
At 24-week intervals from Baseline up to Week 48
|
|
Immune biomarker analysis (immune cell subfractionation analysis)
大体时间:At 24-week intervals from Baseline up to Week 48
|
The subsets of immune cells will be measured, and changes in the levels will be aggregated. |
At 24-week intervals from Baseline up to Week 48
|
|
Metabolome analysis
大体时间:At Baseline
|
A detailed characterization of the patients' metabolome at baseline will be conducted. |
At Baseline
|
|
Adverse events
大体时间:From Baseline up to Week 48
|
The number of adverse events will be aggregated. |
From Baseline up to Week 48
|
|
Vital signs (body temperature)
大体时间:Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 8, 12, 24, 25, 26, 27, 28, 32, 36, and 48
|
Summary statistics of vital signs will be calculated to monitor changes over time. |
Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 8, 12, 24, 25, 26, 27, 28, 32, 36, and 48
|
|
Vital signs (blood pressure)
大体时间:Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 8, 12, 24, 25, 26, 27, 28, 32, 36, and 48
|
Summary statistics of vital signs will be calculated to monitor changes over time. |
Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 8, 12, 24, 25, 26, 27, 28, 32, 36, and 48
|
|
Vital signs (pulse rate)
大体时间:Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 8, 12, 24, 25, 26, 27, 28, 32, 36, and 48
|
Summary statistics of vital signs will be calculated to monitor changes over time. |
Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 8, 12, 24, 25, 26, 27, 28, 32, 36, and 48
|
|
Serum immunoglobulins (IgG)
大体时间:At 4-week intervals from Baseline up to Week 48
|
Summary statistics of serum immunoglobulins will be calculated to monitor changes over time. |
At 4-week intervals from Baseline up to Week 48
|
|
Serum immunoglobulins (IgM)
大体时间:At 4-week intervals from Baseline up to Week 48
|
Summary statistics of serum immunoglobulins will be calculated to monitor changes over time. |
At 4-week intervals from Baseline up to Week 48
|
|
Serum immunoglobulins (IgA)
大体时间:At 4-week intervals from Baseline up to Week 48
|
Summary statistics of serum immunoglobulins will be calculated to monitor changes over time. |
At 4-week intervals from Baseline up to Week 48
|
|
Rituximab concentration of the blood plasma
大体时间:Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 12, 24, 25, 26, 27, 28, 36, and 48
|
Rituximab concentration of the blood plasma |
Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 12, 24, 25, 26, 27, 28, 36, and 48
|
|
Blood drug concentration Anti-Drug Antibody (ADA)
大体时间:Assessments will be conducted at baseline and at Weeks 4, 12, 24, 28, 36, and 48.
|
Summary statistics of ADA will be calculated to monitor changes over time. |
Assessments will be conducted at baseline and at Weeks 4, 12, 24, 28, 36, and 48.
|
|
B cells (CD19/CD20 positive cells) and T cells (CD3/CD4/CD8 positive cells)
大体时间:Assessments will be conducted at baseline and at Weeks 1, 12, 24, 25, 36, and 48.
|
Summary statistics of B cells and T cells will be calculated to monitor changes over time. |
Assessments will be conducted at baseline and at Weeks 1, 12, 24, 25, 36, and 48.
|
合作者和调查者
调查人员
- 首席研究员:Tomoko Okamoto, MD、National Center of Neurology and Psychiatry
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.